114 related articles for article (PubMed ID: 19062264)
1. Use of rasH2 transgenic mice for carcinogenesis testing of medical implants.
Palazzi X; Kergozien-Framery S
Exp Toxicol Pathol; 2009 Sep; 61(5):433-41. PubMed ID: 19062264
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
[TBL] [Abstract][Full Text] [Related]
3. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
4. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature.
Nambiar PR; Turnquist SE; Morton D
Toxicol Pathol; 2012 Jun; 40(4):614-23. PubMed ID: 22328410
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenic susceptibility of rasH2 mice to troglitazone.
Jin M; Takahashi M; Moto M; Muguruma M; Ito K; Watanabe K; Kenmochi Y; Kono T; Hasumi K; Mitsumori K
Arch Toxicol; 2007 Dec; 81(12):883-94. PubMed ID: 17569031
[TBL] [Abstract][Full Text] [Related]
8. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice.
Okamura M; Unami A; Moto M; Muguruma M; Ito T; Jin M; Oishi Y; Kashida Y; Mitsumori K
Cancer Lett; 2007 Jan; 245(1-2):321-30. PubMed ID: 16530936
[TBL] [Abstract][Full Text] [Related]
9. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
10. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
11. Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model.
Umemura T; Kodama Y; Nishikawa A; Hioki K; Nomura T; Kanki K; Kuroiwa Y; Ishii Y; Kurokawa Y; Hirose M
Cancer Lett; 2006 Jan; 231(2):314-8. PubMed ID: 16399233
[TBL] [Abstract][Full Text] [Related]
12. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Long GG; Morton D; Peters T; Short B; Skydsgaard M
Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
[TBL] [Abstract][Full Text] [Related]
13. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
14. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
[TBL] [Abstract][Full Text] [Related]
15. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
16. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
17. Incidence of spontaneous non-neoplastic lesions in transgenic CBYB6F1-Tg(HRAS)2Jic mice.
Paranjpe MG; Shah SA; Denton MD; Elbekai RH
Toxicol Pathol; 2013; 41(8):1137-45. PubMed ID: 23427275
[TBL] [Abstract][Full Text] [Related]
18. Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.
Urano K; Tamaoki N; Nomura T
Vet Pathol; 2012 Jan; 49(1):16-23. PubMed ID: 22146850
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
20. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
